Table 2.

Summary of the significant associations of risk factors and circulating biomarkers with cancer survival via Mendelian randomization analysis

		Significant associations with overall survival						Significant associations with cancer-specific survival
Cancer type	No. of SNPs	Lambda	SNPsa	Locia	Phenotypesb	Genesc	CpG sitesc	Lambda	SNPsa	Locia	Phenotypesb	Genesc	CpG sitesc
Bladder cancer	8 326 282	1.03	34	23	12	710	4692	1.03	134	38	13	737	5017
Brain cancer	8 390 743	1.12	108	39	4	847	5514	1.12	98	38	4	877	5574
Breast cancer	8 338 638	1.01	99	15	11	705	4681	1.01	29	12	14	677	4731
Colorectal cancer	8 334 629	1.01	7	5	5	692	4425	1.01	10	7	15	689	4301
Corpus Uteri	8 360 934	1.01	161	35	7	629	4774	0.98	138	31	8	708	4700
Esophagus cancer	8 296 714	1.07	47	36	9	717	5034	1.07	36	31	7	729	5198
Gastric cancer	8 283 963	1.06	177	50	11	743	4953	1.07	270	54	12	716	5117
Lung cancer	8 355 227	1.01	24	4	12	677	4518	1.01	13	9	13	666	4678
Lymphoid Leukaemia	8 425 952	0.97	98	57	12	757	5208	0.84	271	36	15	792	5142
Multiple Myeloma	8 258 091	1.07	73	39	12	680	4861	1.05	104	41	13	710	5041
Oral and pharynx cancer	8 272 464	1.05	99	30	9	762	4802	0.99	80	39	13	760	4819
Ovarian cancer	8 351 777	1.07	138	48	11	713	4978	1.06	90	46	6	671	4856
Pancreatic cancer	8 299 001	1.07	29	22	9	700	4746	1.06	86	26	10	678	4512
Prostate cancer	8 333 069	1.01	15	11	13	703	4559	1.00	29	9	18	719	4415
Renal cancer	8 376 852	1.03	32	17	11	754	5007	1.03	91	24	6	728	4712
Skin Melanoma	8 339 443	0.99	55	22	14	668	4350	0.96	60	25	16	679	4635
Thyroid cancer	8 308 306	0.77	13	7	23	721	4977	0.37	0	0	12	451	2491

^a P-value for Cox regression model ≤ 1 × 10^–6.

^b P-value for IVW analysis ≤0.05, P-value for egger intercept >0.05, and P-value for heterogeneity >0.05.

^c P-value for SMR analysis ≤0.05 and P-value for HEIDI >0.05.

Note: SNP, single nucleotide polymorphism; IVW, inverse‐variance weighted; SMR, summary-data-based Mendelian randomization.